Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic Equivalence of Azelastine/Fluticasone vs Dymista in SAR
NCT02249663Phase 3Unknown
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Aug 2014
- Primary completion
- Feb 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of azelastine and fluticasone propionate nasal spray in seasonal allergic rhinitis (SAR) (3 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Reflective Total Nasal Symptom Score. Status: unknown.
02
Drugs
azelastinefluticasone propionate nasal spray
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT02249663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02249663.